Fast Five Quiz: Molecular and Biomarker Analysis in Non–Small Cell Lung Cancer (NSCLC)

Daniel S. Schwartz, MD

January 28, 2022

The exon 20 T790M mutation is most common resistance associated with first- and second-generation EGFR tyrosine kinase inhibitor therapy. However, treatment decisions may be affected significantly by the sensitivity of the mutation detection method used and by the testing frequency. Other mutations in exons 18-21 include exon 18 G719X mutations, which are relatively uncommon in NSCLC, as well as exon 19 deletions and exon 21 L858R substitution mutations, which comprise approximately 85% of mutations in NSCLC.

Learn more about EGFR mutations in NSCLC.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Daniel S. Schwartz. Fast Five Quiz: Molecular and Biomarker Analysis in Non–Small Cell Lung Cancer (NSCLC) - Medscape - Jan 28, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.